Think Neuro

Think PNI

A new self-administered drug for the treatment of Multiple Sclerosis has been approved by the US Food and Drug Administration (FDA). In a clinical trial, it outperformed an existing oral drug, with respect to decreasing relapses and new areas of nerve damage seen on MRI….

As physicians, we understand the tremendous value of cognitive, physical, and social activity in optimizing and preserving our abilities as we age. At first glance, it is easy to see COVID as an obstacle. However, there are many ways we can emerge from this period sharper, stronger and more resilient.

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine…

Drug shows encouraging signs for patients of less common type of dementia. Pacific Neuroscience Institute located at Providence Saint John’s Health Center among sites for clinical trial.